Welcome to our dedicated page for Takeda Pharm SEC filings (Ticker: TAK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Takeda Pharmaceutical Company Limited American Depositary Shares (NYSE: TAK) on Stock Titan provides access to the company’s U.S. regulatory disclosures, primarily furnished on Form 20-F and Form 6-K as a foreign private issuer. Takeda prepares its consolidated financial statements in accordance with International Financial Reporting Standards (IFRS) and uses these filings to report semi-annual and annual results, management guidance and material developments in its business.
Recent Form 6-K submissions include English translations of Takeda’s semi-annual securities report and earnings report (Kessan Tanshin) for the six-month period ended September 30, 2025. These documents present revenue by business area (Gastroenterology, Rare Diseases, Plasma-Derived Therapies, Oncology, Vaccines, Neuroscience and Other) and by geographic region, along with operating profit, net profit, cash flow information and explanations of non-IFRS core measures such as core revenue, core operating profit and core EPS. They also discuss factors affecting performance, including generic erosion of specific products, foreign exchange impacts and changes in product mix.
Takeda’s 6-K filings additionally furnish press releases that describe key R&D and strategic events, such as Phase 3 data for zasocitinib (TAK-279) in plaque psoriasis, longer-term VERIFY and THRIVE results for rusfertide in polycythemia vera, portfolio decisions like discontinuation of cell therapy efforts, and revised forecasts for FY2025 revenue and profit. These exhibits provide context on how clinical outcomes, impairments of intangible assets and strategic partnerships influence Takeda’s financial outlook.
Through Stock Titan, users can review Takeda’s SEC filings as they are posted, while AI-powered tools can help summarize lengthy IFRS financial reports, highlight changes in management guidance, and surface important disclosures related to pipeline programs, impairments, capital allocation and regional performance. This makes it easier to understand how Takeda’s global biopharmaceutical operations and late-stage pipeline are reflected in its official U.S. regulatory documents.
Takeda Pharmaceutical Co. Ltd. director Kimberly A. Reed filed an initial beneficial ownership report showing a mix of share holdings and equity awards. She reports direct holdings of 9,700 Ordinary Shares and 8,975 American Depositary Shares. The filing also lists several Tax Obligation Awards, each economically equivalent to one Ordinary Share, covering 1,152, 1,192 and 1,180 underlying Ordinary Shares with vesting and expiration dates on June 1 of 2026, 2027 and 2028. Footnotes explain that separate restricted stock unit awards will vest in tranches of 3,100, 3,400 and 3,200 Ordinary Shares on those same dates, with each RSU converting into one Ordinary Share and then into an equivalent number of American Depositary Shares following vest.
Takeda Pharmaceutical executive Rhonda Janice Pacheco, President of the U.S. Business Unit, filed an initial statement of ownership showing holdings of 149,252 American Depositary Shares. This amount represents an award of restricted stock units, each convertible into one ADS, subject to a multi-year vesting schedule.
The RSUs vest in three equal time-based tranches: 49,750 shares on July 1, 2026, 49,750 shares on July 1, 2027, and 49,752 shares on July 1, 2028. All shares are reported as directly owned, reflecting a significant equity-based compensation grant that aligns the executive’s interests with long-term company performance.
Takeda Pharmaceutical Co Ltd director Michel Bruno Orsinger has filed an initial ownership report detailing his equity interests in the company. The filing lists direct holdings of 7,600 American Depositary Shares and 9,700 Ordinary Shares. It also shows several equity-based awards, including Tax Obligation Awards economically equivalent to 1,152, 1,192 and 1,180 Ordinary Shares, scheduled to vest on different future dates. A cash-settled retirement award is tied to 6,532 Ordinary Shares. Footnotes describe additional restricted stock unit grants that convert into Ordinary Shares or cash upon vesting, with specified vesting dates and retirement-based vesting conditions.
Takeda Pharmaceutical Global Quality Officer Shannon Elaine Mary reported beneficial ownership of 57,580 American Depositary Shares. This filing is an initial ownership report, not a new buy or sell transaction.
The holding includes 27,146 restricted stock units, each equal to one ADS, vesting in tranches on July 1, 2026 (13,144 shares), July 1, 2027 (8,796 shares) and July 1, 2028 (5,206 shares).
Takeda Pharmaceutical director Jean Luc Butel filed an initial ownership report showing his current equity-related interests in the company. He holds 7,600 American Depositary Shares and 9,700 Ordinary Shares directly. The filing also lists several incentive awards tied to Takeda’s stock.
These include Tax Obligation Awards economically equivalent to 1,152, 1,192, and 1,180 Ordinary Shares, each with a 0 exercise price and expirations in 2026, 2027, and 2028, which will be settled in cash mainly to cover tax obligations. A Cash Settled Retirement Award references 6,532 Ordinary Shares and pays cash equal to share value when the director retires. Footnotes describe additional restricted stock units that convert into Ordinary Shares and then ADS upon vesting on June 1, 2026, 2027, and 2028.
TAKEDA PHARMACEUTICAL CO LTD director Miki Tsusaka has reported initial equity interests in the company. The filing shows direct ownership of 6,400 Ordinary Shares. It also lists restricted stock units that vest in tranches of 2,100 shares on June 1, 2026, 2,200 shares on June 1, 2027 and 2,100 shares on June 1, 2028. In addition, the report includes Tax Obligation Awards that are each economically equivalent to one Ordinary Share and are designed to be settled in cash at future vesting dates primarily to cover tax obligations.
Takeda Pharmaceutical’s Chief Financial Officer Furuta Milano has filed an initial ownership report showing existing equity interests. The filing lists direct ownership of 50,100 Ordinary Shares, including 19,500 restricted stock units (RSUs).
The RSUs represent a contingent right to receive one Ordinary Share each, vesting on June 1, 2026 (8,400 shares), June 1, 2027 (7,100 shares) and June 1, 2028 (4,000 shares). The report also shows several Tax Obligation Awards, each economically equivalent to one Ordinary Share, that upon vest will be settled in cash primarily to cover tax obligations at the then-current market price, rather than delivering shares. These entries reflect reported holdings rather than open‑market buying or selling.
Takeda Pharmaceutical’s President and CEO Christophe Weber has reported his initial ownership position on a Form 3. The filing lists direct holdings of 935,300 Ordinary Shares and 253,433 American Depositary Shares, plus various equity-based awards tied to future vesting dates.
The position includes 96,000 restricted stock units (RSUs) linked to Ordinary Shares, vesting on June 1, 2026 (46,100 shares), June 1, 2027 (32,700 shares) and June 1, 2028 (17,200 shares. It also includes 204,008 RSUs linked to American Depositary Shares, vesting on July 1, 2026 (95,744 shares), July 1, 2027 (72,384 shares) and July 1, 2028 (35,850 shares).
Weber also holds Tax Obligation Awards that are economically equivalent to Ordinary Shares, with underlying amounts of 46,367, 32,966 and 17,296 Ordinary Shares, expiring on June 1, 2026, June 1, 2027 and June 1, 2028. Upon vesting, these Tax Obligation Awards convert into cash payments primarily to cover tax obligations based on the then-current Ordinary Share price.
Takeda Pharmaceutical director John Maraganore reports his equity interests in the company. He shows direct holdings of 7,600 American Depositary Shares and 9,700 Ordinary Shares, along with Tax Obligation Awards that are economically equivalent to 1,152, 1,192 and 1,180 Ordinary Shares.
The filing also describes restricted stock unit awards that each convert into one Ordinary Share and then into an equivalent number of American Depositary Shares. These RSUs vest in tranches of 3,100, 3,400 and 3,200 shares on June 1, 2026, June 1, 2027 and June 1, 2028, respectively.
Takeda Pharmaceutical executive Giles Richard Platford, President of PDT, filed an initial ownership report showing beneficial ownership of 225,239 American Depositary Shares. This total includes 94,620 restricted stock units, each representing a contingent right to receive one American Depositary Share.
The restricted stock units vest over three dates: 44,638 shares on July 1, 2026, 32,396 shares on July 1, 2027, and 17,586 shares on July 1, 2028. These awards reflect equity-based compensation that will convert into shares only as they vest over time.